Cargando…

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

OBJECTIVES: Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety and efficacy of mipomersen in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGowan, Mary P., Tardif, Jean-Claude, Ceska, Richard, Burgess, Lesley J., Soran, Handrean, Gouni-Berthold, Ioanna, Wagener, Gilbert, Chasan-Taber, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496741/ https://www.ncbi.nlm.nih.gov/pubmed/23152839 http://dx.doi.org/10.1371/journal.pone.0049006

Ejemplares similares

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
por: Bell, Damon A, et al.
Publicado: (2012)

Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers
por: Flaim, JoAnn D., et al.
Publicado: (2014)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
por: Chambergo-Michilot, Diego, et al.
Publicado: (2022)

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2012)

The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials
por: Astaneh, Behrooz, et al.
Publicado: (2021)

Homozygous familial hypercholesterolemia with an update on cholesterol management
por: Velvet, Anju J J, et al.
Publicado: (2020)

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
por: Visser, Maartje E., et al.
Publicado: (2012)

Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C
por: Schaefer, Esperance A K, et al.
Publicado: (2016)

Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides
por: Gouni-Berthold, Ioanna
Publicado: (2019)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015)

Writing Dissertation and Grant Proposals
por: Chasan-Taber, Lisa
Publicado: (2014)

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
por: Santos, Raul D., et al.
Publicado: (2015)

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

Updates in Drug Treatment of Severe Hypertriglyceridemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2023)

Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans
por: Berthold, Heiner K., et al.
Publicado: (2011)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
por: Katzmann, Julius L., et al.
Publicado: (2020)

Evidence-based goals in LDL-C reduction
por: Soran, Handrean, et al.
Publicado: (2017)

Cardiovascular Risk in Type 1 Diabetes Mellitus
por: Schofield, Jonathan, et al.
Publicado: (2019)

Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
por: Berthold, Heiner K., et al.
Publicado: (2013)

COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
por: Myers, Kelly D., et al.
Publicado: (2021)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Sex Disparities in the Treatment and Control of Cardiovascular Risk Factors in Type 2 Diabetes
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2008)

The role of insulin detemir in overweight type 2 diabetes management
por: Demssie, Yared N, et al.
Publicado: (2009)

Paraoxonase 1 and atherosclerosis
por: Durrington, Paul N., et al.
Publicado: (2023)

Patterns and predictors of statin prescription in patients with type 2 diabetes
por: Berthold, Heiner K, et al.
Publicado: (2009)

Antioxidant properties of HDL
por: Soran, Handrean, et al.
Publicado: (2015)

The role of the renin–angiotensin system blocking in the management of atrial fibrillation
por: Cliff, Brett, et al.
Publicado: (2012)

Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review
por: Alam, Uazman, et al.
Publicado: (2021)

Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
por: Soran, Handrean, et al.
Publicado: (2022)

Maximizing the Outcomes in Cancer Patients Receiving
por: Mucenski, John W., et al.
Publicado: (2003)

Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial
por: Berthold, Heiner K., et al.
Publicado: (2014)

A proof-of-concept study of cascade screening for Familial Hypercholesterolemia in the US, adapted from the Dutch model
por: McGowan, Mary P., et al.
Publicado: (2021)

Anti‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
por: Descamps, Olivier S., et al.
Publicado: (2017)

Postpartum Screening for Diabetes Among Women With a History of Gestational Diabetes Mellitus
por: Tovar, Alison, et al.
Publicado: (2011)

Strategies for recruiting Hispanic women into a prospective cohort study of modifiable risk factors for gestational diabetes mellitus
por: Chasan-Taber, Lisa, et al.
Publicado: (2009)

Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics
por: Altschmiedova, Tereza, et al.
Publicado: (2022)

The impact of lipoprotein lipase deficiency on health-related quality of life: a detailed, structured, qualitative study
por: Neelamekam, Sasi, et al.
Publicado: (2017)

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
por: Rosenson, Robert S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_92gceu2m5ardr9ap1sas1bc14b